Patents by Inventor Yves Dubaquie

Yves Dubaquie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for treating cartilage disorders
    Patent number: 8110548
    Abstract: The present invention relates to a method for the treatment of a cartilage disorder, including cartilage damaged by injury or degenerative cartilagenous disorders. The method involves contacting the cartilage with an IGF-1 analog with altered affinity for IGF-binding proteins (IGFBPs) or an IGFBP displacer peptide that prevents the interaction of an IGF with an IGFBP and does not bind to a human IGF receptor.
    Type: Grant
    Filed: November 2, 2007
    Date of Patent: February 7, 2012
    Assignee: Genentech, Inc.
    Inventors: Yvonne Man-Yee Chen, Ross G. Clark, Andrea G. Cochran, Yves Dubaquie, Paul J. Fielder, Ellen Filvaroff, Henry B. Lowman, Deborah L. Mortensen, Iain C. A. F. Robinson, Nicholas J. Skelton
  • IGF-I protein variants for treating IGFBP-1-related disorders
    Patent number: 8097587
    Abstract: IGF-I variants having an alanine, glycine, or serine amino acid residue at position 16, 25, 49 or at positions 3 and 49 of native-sequence IGF-I are provided that are useful to treat a disorder characterized by dysregulation of the GH/IGF axis in a mammal, such as a renal disorder.
    Type: Grant
    Filed: August 28, 2006
    Date of Patent: January 17, 2012
    Assignee: Genentech, Inc.
    Inventors: Yves Dubaquie, Paul J. Fielder, Henry B. Lowman, Deborah L. Mortensen
  • Article of manufacture
    Patent number: 7947650
    Abstract: The present invention relates to a method for the treatment of a cartilage disorder, including cartilage damaged by injury or degenerative cartilagenous disorders. The method involves contacting the cartilage with an IGF-1 analog with altered affinity for IGF-binding proteins (IGFBPs) or an IGFBP displacer peptide that prevents the interaction of an IGF with an IGFBP and does not bind to a human IGF receptor.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: May 24, 2011
    Assignee: Genentech, Inc.
    Inventors: Yvonne Man-Yee Chen, Ross G. Clark, Andrea G. Cochran, Yves Dubaquie, Paul J. Fielder, Ellen Filvaroff, Henry B. Lowman, Deborah L. Mortensen, Iain C. A. F. Robinson, Nicholas J. Skelton
  • Protein variants
    Publication number: 20110003746
    Abstract: IGF-I variants having an alanine, glycine, or serine amino acid residue at position 16, 25, 49 or at positions 3 and 49 of native-sequence IGF-I are provided that are useful to treat a disorder characterized by dysregulation of the GH/IGF axis in a mammal, such as a renal disorder.
    Type: Application
    Filed: August 28, 2006
    Publication date: January 6, 2011
    Inventors: Yves Dubaquie, Paul J. Fielder, Henry B. Lowman, Deborah L. Mortensen
  • METHOD FOR TREATING CARTILAGE DISORDERS
    Publication number: 20100130411
    Abstract: The present invention relates to a method for the treatment of a cartilage disorder, including cartilage damaged by injury or degenerative cartilagenous disorders. The method involves contacting the cartilage with an IGF-1 analog with altered affinity for IGF-binding proteins (IGFBPs) or an IGFBP displacer peptide that prevents the interaction of an IGF with an IGFBP and does not bind to a human IGF receptor.
    Type: Application
    Filed: November 2, 2007
    Publication date: May 27, 2010
    Inventors: Yvonne Man-Yee Chen, Ross G. Clark, Andrea G. Cochran, Yves Dubaquie, Paul J. Fielder, Ellen Filvaroff, Henry B. Lowman, Deborah L. Mortensen, Iain C.A.F. Robinson, Nicholas J. Skelton
  • METHOD FOR TREATING CARTILAGE DISORDERS
    Publication number: 20090011988
    Abstract: The present invention relates to a method for the treatment of a cartilage disorder, including cartilage damaged by injury or degenerative cartilagenous disorders. The method involves contacting the cartilage with an IGF-1 analog with altered affinity for IGF-binding proteins (IGFBPs) or an IGFBP displacer peptide that prevents the interaction of an IGF with an IGFBP and does not bind to a human IGF receptor.
    Type: Application
    Filed: October 30, 2007
    Publication date: January 8, 2009
    Inventors: Yvonne Man-Yee Chen, Ross G. Clark, Andrea G. Cochran, Yves Dubaquie, Paul J. Fielder, Ellen Filvaroff, Henry B. Lowman, Deborah L. Mortensen, Iain C.A.F. Robinson, Nicholas J. Skelton
  • Method for treating cartilage disorders
    Patent number: 7423017
    Abstract: The present invention relates to a method for the treatment of a cartilage disorder, including cartilage damaged by injury or degenerative cartilagenous disorders. The method involves contacting the cartilage with an IGF-1 analog with altered affinity for IGF-binding proteins (IGFBPs) or an IGFBP displacer peptide that prevents the interaction of an IGF with an IGFBP and does not bind to a human IGF receptor.
    Type: Grant
    Filed: October 16, 2002
    Date of Patent: September 9, 2008
    Assignee: Genentech, Inc.
    Inventors: Yvonne Man-Yee Chen, Ross G. Clark, Andrea G. Cochran, Yves Dubaquie, Paul J. Fielder, Ellen Filvaroff, Henry B. Lowman, Deborah L. Mortensen, Iain C. A. F. Robinson, Nicholas J. Skelton
  • Methods for treating clinical manifestations of GH/GF axis dysregulation by administration of an IGF-I variant
    Patent number: 7105167
    Abstract: IGF-I variants having an alanine, glycine, or serine amino acid residue at position 16, 25, 49 or at positions 3 and 49 of native-sequence IGF-I are provided that are useful to treat a disorder characterized by dysregulation of the GH/IGF axis in a mammal, such as a renal disorder.
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: September 12, 2006
    Assignee: Genentech, Inc.
    Inventors: Yves Dubaquie, Paul J. Fielder, Henry B. Lowman, Deborah L. Mortensen
  • Modified mature insulin variants and composition containing same
    Publication number: 20040033951
    Abstract: IGF-I and insulin variants are provided that selectively bind to IGFBP-1 or IGFBP-3. These agonist variants are useful, for example, to improve the half-lives of IGF-I and insulin, respectively.
    Type: Application
    Filed: May 22, 2003
    Publication date: February 19, 2004
    Inventors: Yves Dubaquie, Henry Lowman
  • Modified mature insulin variants and composition containing same
    Publication number: 20040033952
    Abstract: IGF-I and insulin variants are provided that selectively bind to IGFBP-1 or IGFBP-3. These agonist variants are useful, for example, to improve the half-lives of IGF-I and insulin, respectively.
    Type: Application
    Filed: May 22, 2003
    Publication date: February 19, 2004
    Inventors: Yves Dubaquie, Henry Lowman
  • Modified proinsulin variants and composition containing same
    Publication number: 20040023883
    Abstract: IGF-I and insulin variants are provided that selectively bind to IGFBP-1 or IGFBP-3. These agonist variants are useful, for example, to improve the half-lives of IGF-I and insulin, respectively.
    Type: Application
    Filed: May 22, 2003
    Publication date: February 5, 2004
    Inventors: Yves Dubaquie, Henry Lowman
  • Method for treating cartilage disorders
    Publication number: 20030211992
    Abstract: The present invention relates to a method for the treatment of a cartilage disorder, including cartilage damaged by injury or degenerative cartilagenous disorders. The method involves contacting the cartilage with an IGF-1 analog with altered affinity for IGF-binding proteins (IGFBPs) or an IGFBP displacer peptide that prevents the interaction of an IGF with an IGFBP and does not bind to a human IGF receptor.
    Type: Application
    Filed: October 16, 2002
    Publication date: November 13, 2003
    Applicant: GENENTECH, INC.
    Inventors: Yvonne Man-Yee Chen, Ross G. Clark, Andrea G. Cochran, Yves Dubaquie, Paul J. Fielder, Ellen Filvaroff, Henry B. Lowman, Deborah L. Mortensen, Iain C.A.F. Robinson, Nicholas J. Skelton
  • Modified proinsulin variants and composition containing same
    Publication number: 20030191065
    Abstract: IGF-I and insulin variants are provided that selectively bind to IGFBP-1 or IGFBP-3. These agonist variants are useful, for example, to improve the half-lives of IGF-I and insulin, respectively.
    Type: Application
    Filed: May 22, 2003
    Publication date: October 9, 2003
    Inventors: Yves Dubaquie, Henry Lowman
  • Method for treating cartilage disorders
    Publication number: 20030069177
    Abstract: The present invention relates to a method for the treatment of a cartilage disorder, including cartilage damaged by injury or degenerative cartilagenous disorders. The method involves contacting the cartilage with an IGF-1 analog with altered affinity for IGF-binding proteins (IGFBPs) or an IGFBP displacer peptide that prevents the interaction of an IGF with an IGFBP and does not bind to a human IGF receptor.
    Type: Application
    Filed: May 16, 2001
    Publication date: April 10, 2003
    Applicant: GENENTECH, INC.
    Inventors: Yves Dubaquie, Ellen Filvaroff, Henry B. Lowman
  • IGF-I point variants
    Patent number: 6509443
    Abstract: IGF-I and insulin variants are provided that selectively bind to IGFBP-1 or IGFBP-3. These agonist variants are useful, for example, to improve the half-lives of IGF-I and insulin, respectively.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: January 21, 2003
    Assignee: Genentech, Inc.
    Inventors: Yves Dubaquie, Henry Lowman
  • IGF-I variants
    Patent number: 6506874
    Abstract: IGF-I and insulin variants are provided that selectively bind to IGFBP-1 or IGFBP-3. These agonist variants are useful, for example, to improve the half-lives of IGF-I and insulin, respectively.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: January 14, 2003
    Assignee: Genentech, Inc.
    Inventors: Yves Dubaquie, Henry Lowman
  • Protein variants
    Publication number: 20020160955
    Abstract: IGF-I variants having an alanine, glycine, or serine amino acid residue at position 16, 25, 49 or at positions 3 and 49 of native-sequence IGF-I are provided that are useful to treat a disorder characterized by dysregulation of the GH/IGF axis in a mammal, such as a renal disorder.
    Type: Application
    Filed: December 19, 2001
    Publication date: October 31, 2002
    Applicant: Genentech, Inc.
    Inventors: Yves Dubaquie, Paul J. Fielder, Henry B. Lowman, Deborah L. Mortensen
  • Insulin-like growth factor-1 protein variants
    Patent number: 6403764
    Abstract: IGF-I variants having an alanine, glycine, or serine amino acid residue at position 16,25,49 or at positions 3 and 49 of native-sequence IGF-I are provided that are useful to treat a disorder characterized by dysregulation of the GH/IGF axis in a mammal, such as a renal disorder.
    Type: Grant
    Filed: January 5, 2000
    Date of Patent: June 11, 2002
    Assignee: Genentech, Inc.
    Inventors: Yves Dubaquie, Paul J. Fielder, Henry B. Lowman